ACP3 and cancer: In spite of this, the connection between secreted PAP and prostate cancer contributed to the development of Sipuleucel-T, the first FDA-approved vaccine for cancer therapy targeting PAP-expressing cells [2] even when in advanced/androgen-independent prostate cancer tissue, the expression of PAP is down-regulated [3].